Skip to results
Modify your search
NARROW
1-20 of 50
Authors: Ph. Gabriel Steg
Journal Article
Apolipoprotein A-I infusions and cardiovascular outcomes in acute myocardial infarction according to baseline LDL-cholesterol levels: the AEGIS-II trial
European Heart Journal, Volume 45, Issue 47, 14 December 2024, Pages 5023–5038, https://doi.org/10.1093/eurheartj/ehae614
Published: 02 September 2024
Journal Article
Comparison of change in lipoprotein(a) mass and molar concentrations by alirocumab and risk of subsequent cardiovascular events in ODYSSEY OUTCOMES
European Journal of Preventive Cardiology, Volume 31, Issue 10, August 2024, Pages e75–e78, https://doi.org/10.1093/eurjpc/zwae110
Published: 19 March 2024
Journal Article
Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial
European Heart Journal, Volume 45, Issue 13, 1 April 2024, Pages 1173–1176, https://doi.org/10.1093/eurheartj/ehad889
Published: 22 January 2024
Journal Article
Do patients benefit from omega-3 fatty acids?
Cardiovascular Research, Volume 119, Issue 18, December 2023, Pages 2884–2901, https://doi.org/10.1093/cvr/cvad188
Published: 22 January 2024
Journal Article
Omega-3 fatty acids for cardiovascular event lowering
European Journal of Preventive Cardiology, Volume 31, Issue 8, June 2024, Pages 1005–1014, https://doi.org/10.1093/eurjpc/zwae003
Published: 03 January 2024
Journal Article
Transiently achieved very low low-density lipoprotein cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial
European Heart Journal, Volume 44, Issue 16, 21 April 2023, Pages 1408–1417, https://doi.org/10.1093/eurheartj/ehad144
Published: 05 March 2023
Journal Article
Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 2, March 2023, Pages 129–137, https://doi.org/10.1093/ehjcvp/pvac045
Published: 11 August 2022
Journal Article
EDITOR'S CHOICE
Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab
European Journal of Preventive Cardiology, Volume 29, Issue 14, October 2022, Pages 1842–1851, https://doi.org/10.1093/eurjpc/zwac107
Published: 16 June 2022
Journal Article
Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm
European Heart Journal, Volume 43, Issue 18, 7 May 2022, Pages 1715–1727, https://doi.org/10.1093/eurheartj/ehac056
Published: 15 February 2022
Journal Article
The reduction in cardiovascular risk in REDUCE-IT is due to eicosapentaenoic acid in icosapent ethyl
European Heart Journal, Volume 42, Issue 47, 14 December 2021, Pages 4865–4866, https://doi.org/10.1093/eurheartj/ehab760
Published: 03 November 2021
Journal Article
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial
European Heart Journal, Volume 41, Issue 44, 21 November 2020, Pages 4245–4255, https://doi.org/10.1093/eurheartj/ehaa649
Published: 14 October 2020
Journal Article
REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 7, Issue 3, May 2021, Pages e61–e63, https://doi.org/10.1093/ehjcvp/pvaa118
Published: 03 October 2020
Journal Article
Relationship between physical activity and long-term outcomes in patients with stable coronary artery disease
European Journal of Preventive Cardiology, Volume 27, Issue 4, 1 March 2020, Pages 426–436, https://doi.org/10.1177/2047487319871217
Published: 29 August 2020
Journal Article
Geographical variations in the prevalence and management of cardiovascular risk factors in outpatients with CAD: Data from the contemporary CLARIFY registry
European Journal of Preventive Cardiology, Volume 22, Issue 8, 1 August 2015, Pages 1056–1065, https://doi.org/10.1177/2047487314547652
Published: 29 August 2020
Journal Article
Metabolic syndrome, diabetes mellitus, or both and cardiovascular risk in outpatients with or at risk for atherothrombosis
European Journal of Preventive Cardiology, Volume 21, Issue 12, 1 December 2014, Pages 1531–1540, https://doi.org/10.1177/2047487313500541
Published: 29 August 2020
Journal Article
Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial
European Journal of Preventive Cardiology, Volume 28, Issue 1, January 2021, Pages 33–43, https://doi.org/10.1177/2047487320941987
Published: 27 July 2020
Journal Article
Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis
European Heart Journal, Volume 41, Issue 24, 21 June 2020, Pages 2248–2258, https://doi.org/10.1093/eurheartj/ehz809
Published: 16 November 2019
Journal Article
Pulse pressure in acute coronary syndromes: Comparative prognostic significance with systolic blood pressure Get access
European Heart Journal. Acute Cardiovascular Care, Volume 8, Issue 4, 1 June 2019, Pages 309–317, https://doi.org/10.1177/2048872617700871
Published: 01 June 2019
Journal Article
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial
European Heart Journal, Volume 40, Issue 33, 1 September 2019, Pages 2801–2809, https://doi.org/10.1093/eurheartj/ehz299
Published: 23 May 2019
Journal Article
Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials
European Heart Journal, Volume 39, Issue 19, 14 May 2018, Pages 1726–1735a, https://doi.org/10.1093/eurheartj/ehy162
Published: 13 April 2018
